Nov 6th, 2009 - CNNMoney
Related topics:
Boston Scientific Corp. (BSX) agreed to pay $296 million to resolve a JusticeDepartment investigation into to product advisories at its Guidant defibrillatorunit.
Shares of the medical-device maker fell 3.1% at $7.80 in premarket trading.Through Thursday, the stock was up 4% for 2009.
Because of the settlement, Boston Scientific now says it had a third-quarterloss of $94 million, or 6 cents a share, not the profit of $200 million, or 11cents a share, it reported last month.
Related stories:
A Warning on Web Sales of Cigarettes
Nov 7th, 2009 - New York Times
RICHMOND, Va. (AP) The Food and Drug Administration said Friday that it had warned several companies to stop selling banned flavored cigarettes to consumers online.
Dr. Donald Baim, 60, interventional cardiology pioneer
Nov 7th, 2009 - Boston
NATICK - Dr. Donald Baim, a renowned cardiologist and medical device executive, died yesterday following surgery to treat a form of cancer, his family said in a statement...
Boston Scientific to Settle DOJ Defibrillator Case
Nov 6th, 2009 - Wall Street Journal
Boston Scientific Corp. will pay $296 million in an agreement with the Justice Department stemming from an investigation into problems with Guidant Corp. defibrillators and a major related recall in 2005.
Boston Scientific Pays $296 Million to Settle Probe
Nov 6th, 2009 - Bloomberg
Nov. 6 (Bloomberg) -- Boston Scientific Corp. agreed to pay$296 million to settle a U.S. Justice Department investigationinto the device maker’s Guidant subsidiary and restated third-quarter results to show a loss.
Boston Scientific reaches pact with DOJ, shares fall
Nov 6th, 2009 - Reuters
CHICAGO (Reuters) - Medical device maker Boston Scientific Corp (BSX.N) reached an agreement with the U.S. Department of Justice related to product recalls issued by its Guidant subsidiary...



